Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more
28 major projects now receive money for new and updated laboratories, equipment, databases and other research infrastructure. In total, the Norwegian Research Council will distribute NOK 1.3 billion.
"We are excited to announce that the project “ATMP Norway – A National Multimodal Infrastructure for ATMP” has been awarded an infrastructure grant from the Research Council (74 MNOK)", says Anna Pasetto, Director of the Center for Advanced Cell Therapy (ACT) at the Section for Cell Therapy, Division for Cancer Treatment, Oslo University Hospital.
On the occasion of Professor Kristian Berg’s retirement, the Institute for Cancer Research and Oslo Cancer Cluster are pleased to announce the symposium “Innovative Approaches for Cancer Targeting” 30th October 2024.
We are proud to present an extraordinary program in the intersection of Reactive Oxygen Species, Photomedicine, Endocytosis and Antibody Drug Conjugates (ADCs). The program includes national and international speakers and has high focus on innovation and clinical implementation of research findings.
The Institute for Cancer Research at Oslo University Hospital celebrated its 70th anniversary with the Norwegian Cancer Symposium 2024 on September 9-10.
The event highlighted the institute's groundbreaking contributions to cancer research, featuring 15 distinguished speakers, 8 selected short talks, 118 posters, and 430 registered participants.
The Porto Municipal Medals ceremony for 2024 was held on July 9th, recognising several individuals and institutions for their distinguished merits and civic achievements. Among the recipients of the Medal of Merit - Gold grade, was Professor Ragnhild A. Lothe from the Norwegian Radiumhospital - Institute for Cancer Research. Professor Lothe has played pivotal role in over 30 years of collaboration with scientists and clinicians at medical institutions in Porto, including IPATIMUP, the Portuguese Oncology Institute, and the University of Porto. This collaboration has resulted in numerous joint scientific papers, PhD degrees, innovation projects, and exchanges of scientific and technological expertise.
The Mayor, Rui Moreira, and the President of the Minicipal Assembly, Sebestião de Azevedo, presented the medal in the presence of the municipal executive council.
A paper entitled "Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping" was published in the highly ranked journal Nature Immunology on July 2. This work will be an important resource when designing new NK cell therapies. The authors have been analyzing transcriptional data from 427 patients and 39 datasets, including 7 solid tumor types (lung, brain, skin, pancreas, prostate, breast, sarcoma). They could identify 6 different functional states of tumor-infiltrating NK cells, and the state of the NK cells correlate with survival for cancer patients.
Tore Skotland and Kirsten Sandvig, Department of Molecular Cell Biology, Institute for Cancer Research, have together with four international experts on mass spectroscopy (MS) analyses of lipids, published a short comment (2 pages with a supplementary of 2 pages) in Nature Reviews Molecular Cell Biology.
The article is entitled “Pitfalls in lipid mass spectroscopy of mammalian samples – a brief guide for biologists”.
From major journals, first or last author from the Institute for Cancer Research
Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L(2024) The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy Br J Cancer(in press) DOI 10.1038/s41416-024-02875-5, PubMed 39390250
Møller P, Seppälä TT, Domiguez-Valentin M, Sampson J(2024) Commentary on Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank J Med Genet(in press) DOI 10.1136/jmg-2024-110385, PubMed 39375027
Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T(2024) Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones Nat Commun, 15(1), 8579 DOI 10.1038/s41467-024-52980-5, PubMed 39362905
Møller P, Seppälä TT, Domiguez-Valentin M, Sampson J(2024) Commentary on Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank J Med Genet(in press) DOI 10.1136/jmg-2024-110385, PubMed 39375027
Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti Aet al.(2024) Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) Eur Urol(in press) DOI 10.1016/j.eururo.2024.09.017, PubMed 39394013
Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L(2024) The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy Br J Cancer(in press) DOI 10.1038/s41416-024-02875-5, PubMed 39390250